The EPIC-Norfolk Study

 

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.

Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, and Piccart M

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Feb 2000

(DOI : 10.1200/JCO.2000.18.4.724)

---